NewAmsterdam Pharma (NAMS) Research & Development (2023 - 2026)
NewAmsterdam Pharma (NAMS) posted Research & Development of $38.0 million for Q1 2026, down 1.52% sequentially from $38.6 million in Q4 2025, and down 15.07% YoY from $44.8 million in Q1 2025.
NewAmsterdam Pharma (NAMS) Research & Development (2023 - 2026) Analysis & Trends
NewAmsterdam Pharma has reported Research & Development for 4 years, with the latest figure at $38.0 million in Q1 2026.
- Quarterly Research & Development fell 15.07% year-over-year to $38.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $135.1 million (down 12.12% YoY) and the FY2025 annual result came in at $141.8 million, down 6.32% from the prior year.
- Research & Development slipped to $38.0 million in Q1 2026 per NAMS's latest filing, from $38.6 million in the prior quarter.
- Over five years, Research & Development peaked at $44.8 million in Q1 2025 and troughed at $27.5 million in Q2 2025.
- A 4-year average of $37.7 million and a median of $38.4 million in 2024 frame the typical range for Research & Development.
- The sharpest annual moves came in 2024 and 2025: Research & Development advanced 11.76% in 2024, then retreated 28.3% in 2025.
- Over 4 years, Research & Development stood at $41.3 million in 2023, then slipped by 15.49% to $34.9 million in 2024, then gained by 10.6% to $38.6 million in 2025, then decreased by 1.52% to $38.0 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $38.0 million, $38.6 million, and $31.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | NewAmsterdam Pharma | 3.17 Bn | 3.17 Bn | - | 41.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 41.67 Mn |
| Mar 31, 2026 | 38.01 Mn |
| Dec 31, 2025 | 38.59 Mn |
| Sep 30, 2025 | 30.97 Mn |
| Jun 30, 2025 | 27.52 Mn |
| Mar 31, 2025 | 44.75 Mn |
| Dec 31, 2024 | 34.90 Mn |
| Sep 30, 2024 | 35.70 Mn |
| Jun 30, 2024 | 38.38 Mn |
| Mar 31, 2024 | 42.43 Mn |
| Dec 31, 2023 | 41.29 Mn |
| Sep 30, 2023 | 43.37 Mn |
| Jun 30, 2023 | 34.34 Mn |
| Mar 31, 2023 | 40.42 Mn |